落ち着いているかの様な新型コロナの変種ですが、2023年夏アメリカ最初に確認された変異株『JN.1』、その後11月ごろから欧州各国（フランス、ポルトガル、デンマーク、スペイン、アイルランド、アイスランド、イギリス、アイスランド、シンガポールなど等で発確認され出しています、冬になり増加速度が速い様です？！

以下、アメリカ国民への感染症対策や啓蒙を担っている政府機関からのプレスリリースから

 

 

 

Update on SARS-CoV-2 Variant JN.1 Being Tracked by CDC

December 8, 2023, 11:45 AM

What to know about JN.1

  • How variants spread: The virus that causes COVID-19 is constantly changing over time. Sometimes these changes allow new variants to spread more quickly or effectively. If that occurs, the new variant may become more common relative to other variants that are circulating.
  • How common: CDC projects that the variant JN.1 comprises an estimated 15–29% of in the United States as of December 8, 2023. More information about these projections, including why JN.1 is appearing on the Nowcast separately for the first time, is available in the section below.
    • CDC projects that JN.1 will continue to increase as a proportion of SARS-CoV-2 genomic sequences. It is currently the fastest-growing variant in the United States.
  • History: JN.1 is closely related to the variant BA.2.86 that CDC has been tracking since August.
    • Even though BA.2.86 and JN.1 sound very different because of the way variants are named, there is only a single change between JN.1 and BA.2.86 in the spike protein.
    • JN.1 was first detected in the United States in September 2023. By the end of October, it made up less than 0.1% of SARS-CoV-2 viruses.
    • Previously, JN.1 was grouped with BA.2.86 on COVID Data Tracker.
  • Impact: The continued growth of JN.1 suggests that it is either more transmissible or better at evading our immune systems. At this time, there is no evidence that JN.1 presents an increased risk to public health relative to other currently circulating variants.
    • There is no indication of increased severity from JN.1 at this time.
    • Updated COVID-19 vaccines are expected to increase protection against JN.1, as they do for other variants.
    • As noted in previous updates, COVID-19 tests and treatments are expected to be effective against JN.1.
    • The rapid growth of JN.1 compared with other variants raises the question of whether this variant might drive an incremental increase in infections.
    • COVID-19 activity is currently increasing in the United States. We expected this increase because COVID-19 has had a pattern of increasing and peaking in late summer, and then again peaking around the new year.
      • Right now, we do not know to what extent JN.1 may be contributing to these increases or possible increases through the rest of December like those seen in previous years. CDC will closely monitor COVID-19 activity and the spread of JN.1.
  • Symptoms: It is not currently known whether JN.1 infection produces different symptoms from other variants.
    • In general, symptoms of COVID-19 tend to be similar across variants.
    • The types of symptoms and how severe they are usually depend more on a person’s immunity and overall health rather than which variant causes the infection.
  • What’s next:
    • COVID-19 activity is likely to increase over the next month. An updated COVID-19 vaccine can help keep you protected against JN.1 and other variants. It’s a great time to get that vaccine if you haven’t received one this fall.
    • Regardless of what variants happen, CDC will continue to track them, working closely with partners around the world to understand how they are spreading and how they respond to vaccines and treatments.

 

 

 

The following two tabs change content below.

村松社長

旅行産業界に身を置いてはや45年。シンガポール航空社の日本でのB２Bリーディングカンパニーから京都の制御機器メーカー傘下旅行社を経て起業して以来早くも28年目に入りました。このコロナ禍で本当の旅行情報を発信するために旅行WEBマガジンを令和3年に立ち上げる。専門は海外の出張など。趣味：散歩ついでのお地蔵さん・神社お詣り、銭湯巡り、映画鑑賞。